miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 10, 2014, Pages 2125-2134

  Feng, Junlan ^a   Yang, Yongzhi ^b   Zhang, Peng ^b   Wang, Feng ^b   Ma, Yanlei ^b   Qin, Huanlong ^b   Wang, Yu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

C Myb; Colorectal cancer; MiR 150

Indexed keywords

MESSENGER RNA; MICRORNA; MIRN150 MICRORNA, HUMAN; PROTEIN C MYB;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MYB; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908042645     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12398     Document Type: Article

References (22)

1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005; 365: 153-65.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
3. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-45.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42.
6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5: 522-31.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33.
9. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11: 228-34.
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-66.
11. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259-69.
12. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8.
13. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-98.
14. Ma Y, Zhang P, Wang F, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012; 61: 1447-53.
15. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99: 15524-9.
16. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999; 18: 3017-33.
17. Biroccio A, Benassi B, D'Agnano I, et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001; 158: 1289-99.
18. Tesch H, Michels M, Jucker M, et al. Heterogeneous expression of c-myb protein in human leukemia detected by simultaneous two color flow cytometric analysis. Leuk Res. 1992; 16: 265-74.
19. Lin YC, Kuo MW, Yu J, et al. c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evol. 2008; 25: 2189-98.
20. Pelicci PG, Lanfrancone L, Brathwaite MD, et al. Amplification of the c-myb oncogene in a case of human acute myelogenous leukemia. Science. 1984; 224: 1117-21.
21. Tomita A, Watanabe T, Kosugi H, et al. Truncated c-Myb expression in the human leukemia cell line TK-6. Leukemia. 1998; 12: 1422-9.
22. Lutwyche JK, Keough RA, Hughes TP, et al. Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. Br J Haematol. 2001; 114: 632-4.